Yan Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Dai has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Zhijian Luo
Department of Ultrasound, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province 646000, China
5 shared publicationsJiahao Li
School of Pharmacy Southwest Medical University Luzhou Sichuan Province China
3 shared publicationsMingxing Li
Department of Ultrasound, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China
3 shared publicationsSaixian Shi
School of Pharmacy Southwest Medical University Luzhou Sichuan Province China
3 shared publicationsXiaofeng Li
School of Pharmacy Southwest Medical University Luzhou Sichuan Province China
3 shared publicationsYe Chen
School of Pharmacy Southwest Medical University Luzhou Sichuan Province China
3 shared publications
Latest Publications
- Open Access
- 16 August 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (8) , e72220
2′‐ FL 's Depiction of the Human Physiological Function Landscape
2′‐fucosyllactose (2′‐FL) is a major fucosylated human milk oligosaccharide characterized by a terminal α1,2‐linked fucose residue, which supports its interactions with gut microbes, host glycan‐recognition systems, and pathogen‐binding sites. This review proposes that 2′‐FL acts mainly through a hierarchical host–microbiota mechanism: it first shapes gut microbial composition, then influences microbial metabolites such as short‐chain fatty acids, and subsequently contributes to intestinal barrier integrity, immune homeostasis, and broader physiological outcomes. Current evidence is strongest for the safety of 2′‐FL‐containing infant formula, its bifidogenic effect, and its role in gut barrier and immune regulation. Preclinical studies further suggest potential benefits in allergy modulation through mast cell stabilization, suppression of Th2‐skewed responses, and enhancement of regulatory immune pathways, as well as inhibition of TLR4/NF‐κB‐mediated inflammation. However, antiviral, metabolic, and neuroprotective effects remain emerging and are mainly supported by in vitro, organoid, animal, or computational studies. By distinguishing clinical evidence from mechanistic and preclinical findings, this review aims to provide a structured and evidence‐based overview of the physiological functions and translational potential of 2′‐FL.
- 16 August 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (8) , e72220
Open Access2′‐ FL 's Depiction of the Human Physiological Function Landscape
2′‐fucosyllactose (2′‐FL) is a major fucosylated human milk oligosaccharide characterized by a terminal α1,2‐linked fucose residue, which supports its interactions with gut microbes, host glycan‐recognition systems, and pathogen‐binding sites. This review proposes that 2′‐FL acts mainly through a hierarchical host–microbiota mechanism: it first shapes gut microbial composition, then influences microbial metabolites such as short‐chain fatty acids, and subsequently contributes to intestinal barrier integrity, immune homeostasis, and broader physiological outcomes. Current evidence is strongest for the safety of 2′‐FL‐containing infant formula, its bifidogenic effect, and its role in gut barrier and immune regulation. Preclinical studies further suggest potential benefits in allergy modulation through mast cell stabilization, suppression of Th2‐skewed responses, and enhancement of regulatory immune pathways, as well as inhibition of TLR4/NF‐κB‐mediated inflammation. However, antiviral, metabolic, and neuroprotective effects remain emerging and are mainly supported by in vitro, organoid, animal, or computational studies. By distinguishing clinical evidence from mechanistic and preclinical findings, this review aims to provide a structured and evidence‐based overview of the physiological functions and translational potential of 2′‐FL.
- Open Access
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1672970
The role of ADAR1 in human pathophysiology
Adenosine deaminase 1 (ADAR1) is an enzyme acting on double-stranded RNA, primarily responsible for catalyzing the adenosine-inosine deamination reaction of dsRNA.An increasing number of studies have demonstrated that ADAR1 plays a pivotal role in various diseases, including cardiovascular, neurological, and immune disorders, among others. Some of these diseases remain incurable. In addition, ADAR1 is also involved in the development and differentiation of various crucial cells, such as hematopoietic stem cells and nerve cells. This article comprehensively summarizes the regulatory effects of ADAR1 on crucial cells and organs across the immune, nervous, respiratory, blood, and digestive systems, along with its influence on disease progression. The aim is to offer assistance in intervening in cells and treating diseases.
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1672970
Open AccessThe role of ADAR1 in human pathophysiology
Adenosine deaminase 1 (ADAR1) is an enzyme acting on double-stranded RNA, primarily responsible for catalyzing the adenosine-inosine deamination reaction of dsRNA.An increasing number of studies have demonstrated that ADAR1 plays a pivotal role in various diseases, including cardiovascular, neurological, and immune disorders, among others. Some of these diseases remain incurable. In addition, ADAR1 is also involved in the development and differentiation of various crucial cells, such as hematopoietic stem cells and nerve cells. This article comprehensively summarizes the regulatory effects of ADAR1 on crucial cells and organs across the immune, nervous, respiratory, blood, and digestive systems, along with its influence on disease progression. The aim is to offer assistance in intervening in cells and treating diseases.
- Open Access
- 9 January 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (1) , e70044
Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
Objective: Provide an evidence‐based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).Methods: Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre‐established inclusion and exclusion criteria. Use the Cochrane bias risk assessment tool to evaluate the quality of the included literature. Use R 4.3.2 software to conduct network meta‐analysis for drug category comparison.Results: A total of 24 large‐scale randomized controlled trials (RCTs) were included, including 19 intervention measures, and 172 803 patients participated in the study. The results of the network meta‐analysis show that: GLP1RA (OR 0.89, 95% CI 0.81–0.97) and SGLT2i (OR 0.91, 95% CI 0.83–0.99) can reduce the occurrence of major adverse cardiovascular events (MACE), GLP1RA (OR 0.88, 95% CI 0.79–0.97) and SGLT2i (OR 0.89, 95% CI 0.81–0.99) reduced the risk of cardiovascular death. SGLT2i (OR 0.68, 95% CI 0.62–0.75) reduced the occurrence of hospitalization for heart failure, GLP1RA (OR 0.88, 95% CI 0.81–0.97) and SGLT2i (OR 0.89, 95% CI 0.80–0.97) reduced the occurrence of all‐cause death.Conclusion: In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all‐cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.
- 9 January 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (1) , e70044
Open AccessCardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
Objective: Provide an evidence‐based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).Methods: Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre‐established inclusion and exclusion criteria. Use the Cochrane bias risk assessment tool to evaluate the quality of the included literature. Use R 4.3.2 software to conduct network meta‐analysis for drug category comparison.Results: A total of 24 large‐scale randomized controlled trials (RCTs) were included, including 19 intervention measures, and 172 803 patients participated in the study. The results of the network meta‐analysis show that: GLP1RA (OR 0.89, 95% CI 0.81–0.97) and SGLT2i (OR 0.91, 95% CI 0.83–0.99) can reduce the occurrence of major adverse cardiovascular events (MACE), GLP1RA (OR 0.88, 95% CI 0.79–0.97) and SGLT2i (OR 0.89, 95% CI 0.81–0.99) reduced the risk of cardiovascular death. SGLT2i (OR 0.68, 95% CI 0.62–0.75) reduced the occurrence of hospitalization for heart failure, GLP1RA (OR 0.88, 95% CI 0.81–0.97) and SGLT2i (OR 0.89, 95% CI 0.80–0.97) reduced the occurrence of all‐cause death.Conclusion: In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all‐cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.
- 31 March 2023
- Published by Elsevier in Cellular Signalling
- Vol. 107, 110665
An update on the molecular mechanism and pharmacological interventions for Ischemia-reperfusion injury by regulating AMPK/mTOR signaling pathway in autophagy
- 31 March 2023
- Published by Elsevier in Cellular Signalling
- Vol. 107, 110665
An update on the molecular mechanism and pharmacological interventions for Ischemia-reperfusion injury by regulating AMPK/mTOR signaling pathway in autophagy
- Top Cited PapersOpen Access
- 14 March 2023
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 21 (1) , 1-20
Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy
Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or in combination in a variety of cancers, while it has been found to cause serious cardiac side effects in clinical application. More and more researchers are trying to explore the molecular mechanisms of DOX-induced cardiomyopathy (DIC), in which oxidative stress and inflammation are considered to play a significant role. This review summarizes signaling pathways related to oxidative stress and inflammation in DIC and compounds that exert cardioprotective effects by acting on relevant signaling pathways, including the role of Nrf2/Keap1/ARE, Sirt1/p66Shc, Sirt1/PPAR/PGC-1α signaling pathways and NOS, NOX, Fe2+signaling in oxidative stress, as well as the role of NLRP3/caspase-1/GSDMD, HMGB1/TLR4/MAPKs/NF-κB, mTOR/TFEB/NF-κB pathways in DOX-induced inflammation. Hence, we attempt to explain the mechanisms of DIC in terms of oxidative stress and inflammation, and to provide a theoretical basis or new idea for further drug research on reducing DIC.
- 14 March 2023
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 21 (1) , 1-20
Top Cited PapersOpen AccessRole of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy
Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or in combination in a variety of cancers, while it has been found to cause serious cardiac side effects in clinical application. More and more researchers are trying to explore the molecular mechanisms of DOX-induced cardiomyopathy (DIC), in which oxidative stress and inflammation are considered to play a significant role. This review summarizes signaling pathways related to oxidative stress and inflammation in DIC and compounds that exert cardioprotective effects by acting on relevant signaling pathways, including the role of Nrf2/Keap1/ARE, Sirt1/p66Shc, Sirt1/PPAR/PGC-1α signaling pathways and NOS, NOX, Fe2+signaling in oxidative stress, as well as the role of NLRP3/caspase-1/GSDMD, HMGB1/TLR4/MAPKs/NF-κB, mTOR/TFEB/NF-κB pathways in DOX-induced inflammation. Hence, we attempt to explain the mechanisms of DIC in terms of oxidative stress and inflammation, and to provide a theoretical basis or new idea for further drug research on reducing DIC.
- Open Access
- 21 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113903
Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
- 21 October 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 156, 113903
Open AccessResearch progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
- 1 November 2021
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 47 (11) , 3253-3262
Quantitative Evaluation of Renal Cortex Perfusion Using Contrast-Enhanced Ultrasound Imaging Parameters in Ischemia–Reperfusion Injury in Rabbits
- 1 November 2021
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 47 (11) , 3253-3262
Quantitative Evaluation of Renal Cortex Perfusion Using Contrast-Enhanced Ultrasound Imaging Parameters in Ischemia–Reperfusion Injury in Rabbits
- Open Access
- 5 October 2020
- Published by Springer Nature in Research Square
Quantitative Evaluation of Renal Cortex Perfusion using Contrast-enhanced Ultrasound Imaging Parameters in Renal Ischemia-reperfusion Injury in Rabbits
Background: Contrast-enhanced ultrasound (CEUS) can be used as a noninvasive and quantitative diagnostic method to judge the progression of renal ischemia-reperfusion injury. The aim of this study was to evaluate the blood perfusion of renal cortex during ischemia-reperfusion (I/R) injury by quantitative contrast-enhanced ultrasound (CEUS) parameters.Materials: In this experiment, 24 rabbits were randomly divided into following four groups (N=6): sham-operation group, 24-h post-operation of ischemia-reperfusion injury group (24-h I/R), 3-d post-operation of I/R injury group (3-d I/R) and 5-d post-operation of I/R injury group (5-d I/R). The I/R model was surgically established. CEUS was performed via a GE LOGIQ 9 ultrasound machine, and a time-intensity curve (TIC) in the renal cortex was generated for each group. All quantitative CEUS parameters were derived from TIC and included the following: the curve's peak ascending slope (wash-in slope [WIS]),area under the curve (AUC), time-to-peak (TTP), change in perfusion peak intensity (A), and arrival time (AT), Subsequently, we analyzed the changes in these parameters, as well as the correlation between changes in CEUS parameters and pathological parameters.Results: The values of AT, TTP, and WIS of all I/R groups significantly differed from the sham-operation group (P 0.05). The AT and TTP values peaked at 3 d after I/R surgery, which correlated with the most significant pathological changes at the same time point.Conclusions: Among the quantitative CEUS parameters, AT, TTP, and WIS were found to be sensitive indicators reflecting blood perfusion in renal microcirculation. Hence, these parameters may be useful for dynamically monitoring the severity of tissue damage at the early stage of I/R injury. Collectively, our findings provide compelling evidence for further clinical application of quantitative CEUS analysis.
- 5 October 2020
- Published by Springer Nature in Research Square
Open AccessQuantitative Evaluation of Renal Cortex Perfusion using Contrast-enhanced Ultrasound Imaging Parameters in Renal Ischemia-reperfusion Injury in Rabbits
Background: Contrast-enhanced ultrasound (CEUS) can be used as a noninvasive and quantitative diagnostic method to judge the progression of renal ischemia-reperfusion injury. The aim of this study was to evaluate the blood perfusion of renal cortex during ischemia-reperfusion (I/R) injury by quantitative contrast-enhanced ultrasound (CEUS) parameters.Materials: In this experiment, 24 rabbits were randomly divided into following four groups (N=6): sham-operation group, 24-h post-operation of ischemia-reperfusion injury group (24-h I/R), 3-d post-operation of I/R injury group (3-d I/R) and 5-d post-operation of I/R injury group (5-d I/R). The I/R model was surgically established. CEUS was performed via a GE LOGIQ 9 ultrasound machine, and a time-intensity curve (TIC) in the renal cortex was generated for each group. All quantitative CEUS parameters were derived from TIC and included the following: the curve's peak ascending slope (wash-in slope [WIS]),area under the curve (AUC), time-to-peak (TTP), change in perfusion peak intensity (A), and arrival time (AT), Subsequently, we analyzed the changes in these parameters, as well as the correlation between changes in CEUS parameters and pathological parameters.Results: The values of AT, TTP, and WIS of all I/R groups significantly differed from the sham-operation group (P 0.05). The AT and TTP values peaked at 3 d after I/R surgery, which correlated with the most significant pathological changes at the same time point.Conclusions: Among the quantitative CEUS parameters, AT, TTP, and WIS were found to be sensitive indicators reflecting blood perfusion in renal microcirculation. Hence, these parameters may be useful for dynamically monitoring the severity of tissue damage at the early stage of I/R injury. Collectively, our findings provide compelling evidence for further clinical application of quantitative CEUS analysis.